Proteasome inhibition rescues clinically significant unstable variants of the mismatch repair protein Msh2

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 1, 2013, Pages 246-251

  Arlow, Tim ^a   Scott, Kristan ^a   Wagenseller, Aubrey ^a   Gammie, Alison ^a  

^a PRINCETON UNIVERSITY   (United States)

Author keywords

Hereditary nonpolyposis clorectal cancer; Lynch syndrome; Mutator; MutS

Indexed keywords

BORTEZOMIB; CISPLATIN; PROTEASOME; PROTEIN MSH2; SAN1 PROTEIN; UBIQUITIN; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; CONTROLLED STUDY; GENE DELETION; GENE DOSAGE; GENE MUTATION; GENETIC VARIABILITY; HUMAN; MISMATCH REPAIR; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN PROTEIN INTERACTION;

BORONIC ACIDS; CISPLATIN; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA MISMATCH REPAIR; DNA PRIMERS; DNA SEQUENCE, UNSTABLE; GENE DOSAGE; GENE EXPRESSION REGULATION; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MODELS, MOLECULAR; MUTATION, MISSENSE; MUTS HOMOLOG 2 PROTEIN; PLASMIDS; POLYMERASE CHAIN REACTION; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS; UBIQUITIN; UBIQUITIN-PROTEIN LIGASES;

EUKARYOTA;

EID: 84871955958     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1215510110     Document Type: Article

References (27)

1. Lynch HT, et al. (2009) Review of the Lynch syndrome: History, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet 76(1):1-18.
2. Poulogiannis G, Frayling IM, Arends MJ (2010) DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome. Histopathology 56(2):167-179.
3. Hsieh P, Yamane K (2008) DNA mismatch repair: molecular mechanism, cancer, and ageing. Mech Ageing Dev 129(7-8):391-407.
4. Kunkel TA, Erie DA (2005) DNA mismatch repair. Annu Rev Biochem 74:681-710. (Pubitemid 40995521)
5. Yang W (2007) Human MutLalpha: the jack of all trades in MMR is also an endonuclease. DNA Repair (Amst) 6(1):135-139.
6. Jover R, et al.; Gastrointestinal Oncology Group of the Spanish Gastroenterological Association (2009) The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer 45(3):365-373.
7. Aebi S, et al. (1996) Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 56(13):3087-3090. (Pubitemid 26199755)
8. Fink D, et al. (1996) The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56(21):4881-4886. (Pubitemid 26374423)
9. Gammie AE, et al. (2007) Functional characterization of pathogenic human MSH2 missense mutations in Saccharomyces cerevisiae. Genetics 177(2):707-721. (Pubitemid 350005626)
10. Jia L, Sun Y (2011) SCF E3 ubiquitin ligases as anticancer targets. Curr Cancer Drug Targets 11(3):347-356.
11. Rosenbaum JC, et al. (2011) Disorder targets misorder in nuclear quality control degradation: A disordered ubiquitin ligase directly recognizes its misfolded substrates. Mol Cell 41(1):93-106.
12. Cambien F (2011) Heritability, weak effects, and rare variants in genomewide association studies. Clin Chem 57(9):1263-1266.
13. Han HJ, et al. (1996) Germline mutations of hMLH1 and hMSH2 genes in Korean hereditary nonpolyposis colorectal cancer. J Natl Cancer Inst 88(18):1317-1319.
14. Furukawa T, et al. (2002) Evaluation of Screening Strategy for Detecting Hereditary Nonpolyposis Colorectal Carcinoma (Wiley & Sons, New York), pp 911-920.
15. Miyakura Y, Sugano K, Nomizu T, Lefor A, Yasuda Y (2012) Pathogenicity of A600V variant in exon 12 of the MSH2 gene detected in a Japanese kindred with Lynch syndrome. Jpn J Clin Oncol 42(1):78-82.
16. Hernandez-Pigeon H, Laurent G, Humbert O, Salles B, Lautier D (2004) Degadration of mismatch repair hMutSalpha heterodimer by the ubiquitin-proteasome pathway. FEBS Lett 562(1-3):40-44. (Pubitemid 38388445)
17. Steele N, Finn P, Brown R, Plumb JA (2009) Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. Br J Cancer 100(5):758-763.
18. DePristo MA, Weinreich DM, Hartl DL (2005) Missense meanderings in sequence space: A biophysical view of protein evolution. Nat Rev Genet 6(9):678-687. (Pubitemid 41192319)
19. Markossian KA, Kurganov BI (2004) Protein folding, misfolding, and aggregation. Formation of inclusion bodies and aggresomes. Biochemistry (Mosc) 69(9):971-984.
20. Gautreau A, et al. (2002) Mutant products of the NF2 tumor suppressor gene are degraded by the ubiquitin-proteasome pathway. J Biol Chem 277(35):31279-31282. (Pubitemid 34968924)
21. Yaguchi H, et al. (2004) Menin missense mutants associated with multiple endocrine neoplasia type 1 are rapidly degraded via the ubiquitin-proteasome pathway. Mol Cell Biol 24(15):6569-6580. (Pubitemid 38944338)
22. Kroeger H, et al. (2009) Endoplasmic reticulum-associated degradation (ERAD) and autophagy cooperate to degrade polymerogenic mutant serpins. J Biol Chem 284(34):22793-22802.
23. Walus M, Kida E, Golabek AA (2010) Functional consequences and rescue potential of pathogenic missense mutations in tripeptidyl peptidase I. Hum Mutat 31(6):710-721.
24. Shi Z, Sellers J, Moult J (2012) Protein stability and in vivo concentration of missense mutations in phenylalanine hydroxylase. Proteins 80(1):61-70.
25. Laney JD, Hochstrasser M (2002) Current Protocols in Protein Science: Analysis of Protein Ubiquitination (Wiley & Sons, New York).
26. Lang GI, Murray AW (2008) Estimating the per-base-pair mutation rate in the yeast Saccharomyces cerevisiae. Genetics 178(1):67-82. (Pubitemid 351398732)
27. Spence J, Sadis S, Haas AL, Finley D (1995) A ubiquitin mutant with specific defects in DNA repair and multiubiquitination. Mol Cell Biol 15(3):1265-1273.